<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00806234</url>
  </required_header>
  <id_info>
    <org_study_id>R01MH080270</org_study_id>
    <secondary_id>R01MH080270</secondary_id>
    <secondary_id>DSIR 84-CTS</secondary_id>
    <nct_id>NCT00806234</nct_id>
  </id_info>
  <brief_title>Reducing Weight Gain and Improving Metabolic Function in Children Being Treated With Antipsychotics</brief_title>
  <acronym>IMPACT</acronym>
  <official_title>Improving Metabolic Parameters of Antipsychotic Child Treatment (IMPACT)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Johns Hopkins University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Institute of Mental Health (NIMH)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
    <collaborator>
      <agency>University of Maryland, College Park</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University of North Carolina, Chapel Hill</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>The Zucker Hillside Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Johns Hopkins University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study will test the effectiveness of two different treatments for children and&#xD;
      adolescents who have gained weight on their antipsychotic medications.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Disorders that involve severe dysregulation of mood or thoughts in children -- such as early&#xD;
      onset bipolar spectrum (BPS) and schizophrenia spectrum (SS) disorders -- are commonly&#xD;
      treated with antipsychotic medications. However, many of the newest and most commonly&#xD;
      prescribed antipsychotic medications can cause weight gain and metabolic dysfunctions. Use of&#xD;
      these newer antipsychotics, called second generation antipsychotics (SGAs), is increasing&#xD;
      rapidly in children, and the risk of weight gain from SGAs is higher among children than&#xD;
      adults. Excessive weight gain can lead to obesity, which, in turn, can lead to increased&#xD;
      health care costs, increased risk of sickness, and lower life expectancy. These factors are&#xD;
      enhanced in children and adolescents who grow up obese.&#xD;
&#xD;
      Two different strategies to reduce weight gain and metabolic side effects from SGAs will be&#xD;
      tested in this study. The first strategy involves switching from the current SGA to a lower&#xD;
      risk agent (aripiprazole or perphenazine) hypothesized to result in weight loss and improved&#xD;
      metabolic functioning. The second strategy involves taking the medication metformin in&#xD;
      addition to the current SGA. Metformin is approved by the Food and Drug Administration (FDA)&#xD;
      to promote weight loss in youth with diabetes and has been effective in reducing weight in&#xD;
      youth taking SGAs.&#xD;
&#xD;
      Participation in this study will last between 26 and 27 weeks and will be divided into two&#xD;
      parts. The first part will last 2 to 3 weeks and include three study visits. During this&#xD;
      part, participants will undergo a physical exam, an electrocardiogram (EKG), a dual energy&#xD;
      X-ray absorptiometry (DXA) test, and blood tests. The DXA measures body fat.&#xD;
&#xD;
      The second part will last 24 weeks and include nine study visits. During this part,&#xD;
      participants will be randomly assigned to one of three conditions: gradual switch of current&#xD;
      SGA medication to either aripiprazole or perphenazine, addition of metformin to current SGA&#xD;
      medication, or no change to treatment with current SGA medication. Visits will take place on&#xD;
      Weeks 1, 2, 4, 6, 8, 12, 16, 20, and 24. At each visit, participants will meet with a study&#xD;
      doctor who will assess symptoms and side effects, and participants and their guardians will&#xD;
      receive information and recommendations about childhood obesity and weight loss. There will&#xD;
      also be monthly urine pregnancy tests, and two blood tests.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>January 2009</start_date>
  <completion_date type="Actual">March 2014</completion_date>
  <primary_completion_date type="Actual">March 2014</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Factorial Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Body Mass Index (BMI) Z-score Change</measure>
    <time_frame>Change from baseline to 24 weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in Whole Body Insulin Sensitivity Index</measure>
    <time_frame>Change from baseline to 24 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Triglyceride Levels</measure>
    <time_frame>Change from baseline to 24 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Low Density Lipoprotein (LDL) Cholesterol Level</measure>
    <time_frame>From Baseline to Week 24</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">127</enrollment>
  <condition>Psychotic Disorders</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Participants will continue on current antipsychotic medication.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will undergo a staggered switch from current antipsychotic medication to aripiprazole or perphenazine.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will add metformin to current antipsychotic medication treatment.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Aripiprazole or Perphenazine</intervention_name>
    <description>Baseline second generation antipsychotic (SGA) treatment will be gradually decreased and discontinued over 8 weeks while treatment with aripiprazole or perphenazine will be increased to effective levels.</description>
    <arm_group_label>2</arm_group_label>
    <other_name>Abilify, Trilafon</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Metformin</intervention_name>
    <description>Metformin treatment will be added to current SGA treatment, with dosing based on participant weight and increased according to a preset titration schedule unless side effects interfere.</description>
    <arm_group_label>3</arm_group_label>
    <other_name>Glucophage</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Olanzapine, quetiapine, risperidone, ziprasidone, aripiprazole, asenapine, iloperidone, lurasidone, paliperidone, or olanzapine/fluoxetine</intervention_name>
    <description>Current antipsychotic medication will be continued throughout the treatment period, with changes in dose only made as clinically indicated</description>
    <arm_group_label>1</arm_group_label>
    <other_name>Zyprexa, Seroquel, Risperdal, Geodon, Abilify, Saphris, Sycrest, Fanapt, Fanapta, Zomaril, Latuda, Invega, Symbyax</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  DSM diagnoses that have an FDA indication for atypical antipsychotic use for at least&#xD;
             one agent in the respective pediatric or adult age group. Specifically, primary DSM-IV&#xD;
             diagnosis of Early Onset Schizophrenia Spectrum (EOSS; schizophrenia, schizoaffective&#xD;
             disorder, schizophreniform disorder, psychotic disorder NOS); Bipolar Spectrum&#xD;
             (bipolar I, II and NOS); Major depressive disorder with psychosis; Mood disorder NOS&#xD;
             corresponding to Leibenluft and colleagues severely mood dysregulated (SMD) broad&#xD;
             spectrum bipolar disorder; Mood disorder NOS corresponding to irritability associated&#xD;
             with autism spectrum disorders; or - for adult teen participants aged 18-19 years -&#xD;
             Major depressive disorder. Diagnoses will be determined by clinical interview,&#xD;
             Leibenluft's modification of the K-SADS-PL, and the &quot;Aberrant Behavior Checklist&quot;&#xD;
             (cutoff score of 18, as used by FDA for approval of risperidone and aripiprazole in&#xD;
             minors).&#xD;
&#xD;
          -  Clinically stable on current treatment regimen for at least 30 days, as assessed in a&#xD;
             three-step process&#xD;
&#xD;
          -  Current SGA treatment with olanzapine, quetiapine, risperidone, ziprasidone&#xD;
             aripiprazole, asenapine, iloperidone, lurasidone, paliperidone, or&#xD;
             olanzapine/fluoxetine for ≥ 8 weeks&#xD;
&#xD;
          -  Stable dose of current SGA and psychotropic co-medications for at least 30 days&#xD;
&#xD;
          -  Body mass index (BMI) at least in the 85th percentile for age and gender&#xD;
&#xD;
          -  Substantial weight gain over the previous 3 years while taking a SGA, as reflected by&#xD;
             family and referring physician's judgment. The weight gain did not have to occur on&#xD;
             the child's current SGA. Weight needs to have remained stable or increased over past&#xD;
             year.&#xD;
&#xD;
          -  Agrees to use two effective forms of birth control or to remain abstinent&#xD;
&#xD;
          -  Has a primary caretaker who has known the child well for at least 6 months before&#xD;
             study entry&#xD;
&#xD;
          -  Primary caretaker is able to participate in study appointments as clinically indicated&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Treatment with any medication (other than the currently prescribed psychotropic&#xD;
             medications) that would significantly alter glucose, insulin, or lipid levels.&#xD;
             Exception: orlistat and amantadine are permitted if the individual has taken the drug&#xD;
             for at least one year without weight loss.&#xD;
&#xD;
          -  Major neurological or medical illness that affects weight gain or that would prevent&#xD;
             participation in physical activities&#xD;
&#xD;
          -  Fasting glucose levels indicating need for prompt treatment&#xD;
&#xD;
          -  Pediatrician or pediatric gastroenterologist recommendation to address abnormal&#xD;
             fasting labs by pursuing more active treatment than those in the 2007 American Medical&#xD;
             Association guidelines&#xD;
&#xD;
          -  Diagnosis of anorexia nervosa or bulimia nervosa, as based on current or lifetime&#xD;
             DSM-IV criteria&#xD;
&#xD;
          -  Diagnosis of substance dependence disorder (other than tobacco dependence) within the&#xD;
             past month, as based on DSM-IV criteria&#xD;
&#xD;
          -  Positive urine toxicology indicating ongoing use of illicit substance&#xD;
&#xD;
          -  Current treatment with more than one antipsychotic medication&#xD;
&#xD;
          -  Current treatment with more than 3 total psychotropic medications (i.e., 2&#xD;
             psychotropics plus SGA), with the exception of subjects taking 2 medications for ADHD&#xD;
             in which a total of 4 psychotropic medications are allowed.&#xD;
&#xD;
          -  Known hypersensitivity to metformin&#xD;
&#xD;
          -  Prior treatment with aripiprazole and perphenazine for more than 2 weeks that was&#xD;
             stopped for inefficacy or intolerability&#xD;
&#xD;
          -  Pregnant, breastfeeding, or unwilling to comply with contraceptive requirements of&#xD;
             study&#xD;
&#xD;
          -  IQ score less than 55&#xD;
&#xD;
          -  Significant risk of dangerousness to self or to others that would make study&#xD;
             participation inadvisable&#xD;
&#xD;
          -  Language issues that prevent child and/or parent from completing assessments or&#xD;
             treatment&#xD;
&#xD;
          -  Ongoing or previously undisclosed child abuse requiring new department of social&#xD;
             service intervention&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>8 Years</minimum_age>
    <maximum_age>19 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Gloria Reeves, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Maryland, College Park</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Linmarie Sikich, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of North Carolina, Division of Child and Adolescent Psychiatry</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Christoph Correll, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>The Zucker Hillside Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Mark A. Riddle, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Johns Hopkins University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Maryland</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21201</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Johns Hopkins Hospital</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21205</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Zucker Hillside Hospital</name>
      <address>
        <city>Glen Oaks</city>
        <state>New York</state>
        <zip>11004</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of North Carolina, Division of Child and Adolescent Psychiatry</name>
      <address>
        <city>Chapel Hill</city>
        <state>North Carolina</state>
        <zip>27599</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Reeves GM, Keeton C, Correll CU, Johnson JL, Hamer RM, Sikich L, Hazzard L, Alderman C, Scheer A, Mabe M, Kapoor S, Sheridan E, Borner I, Bussell K, Pirmohamed S, Bethea TC, Chekuri R, Gottfried R, Reinblatt SP, Santana E, Riddle MA. Improving metabolic parameters of antipsychotic child treatment (IMPACT) study: rationale, design, and methods. Child Adolesc Psychiatry Ment Health. 2013 Aug 15;7(1):31. doi: 10.1186/1753-2000-7-31.</citation>
    <PMID>23947389</PMID>
  </reference>
  <verification_date>April 2017</verification_date>
  <study_first_submitted>December 9, 2008</study_first_submitted>
  <study_first_submitted_qc>December 9, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 10, 2008</study_first_posted>
  <results_first_submitted>July 2, 2016</results_first_submitted>
  <results_first_submitted_qc>April 21, 2017</results_first_submitted_qc>
  <results_first_posted type="Actual">April 25, 2017</results_first_posted>
  <last_update_submitted>April 21, 2017</last_update_submitted>
  <last_update_submitted_qc>April 21, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">April 25, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Johns Hopkins University</investigator_affiliation>
    <investigator_full_name>Mark Riddle, MD</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <keyword>Weight Gain</keyword>
  <keyword>Obesity</keyword>
  <keyword>IMPACT</keyword>
  <keyword>Antipsychotic Treatment</keyword>
  <keyword>Excessive Weight Gain Associated With Antipsychotic Treatment</keyword>
  <keyword>Hybrid Efficacy/Effectiveness Design</keyword>
  <keyword>Reducing Weight Gain</keyword>
  <keyword>Improving Metabolic Parameters</keyword>
  <keyword>Aripiprazole</keyword>
  <keyword>Metformin</keyword>
  <keyword>Risperdal</keyword>
  <keyword>Seroquel</keyword>
  <keyword>Quetiapine</keyword>
  <keyword>Olanzapine</keyword>
  <keyword>Zyprexa</keyword>
  <keyword>Geodon</keyword>
  <keyword>Risperidone</keyword>
  <keyword>Abilify</keyword>
  <keyword>Trilafon</keyword>
  <keyword>Perphenazine</keyword>
  <keyword>Glucophage</keyword>
  <keyword>Paliperidone</keyword>
  <keyword>Olanzapine/fluoxetine</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Weight Gain</mesh_term>
    <mesh_term>Mental Disorders</mesh_term>
    <mesh_term>Psychotic Disorders</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Metformin</mesh_term>
    <mesh_term>Olanzapine</mesh_term>
    <mesh_term>Risperidone</mesh_term>
    <mesh_term>Quetiapine Fumarate</mesh_term>
    <mesh_term>Aripiprazole</mesh_term>
    <mesh_term>Paliperidone Palmitate</mesh_term>
    <mesh_term>Ziprasidone</mesh_term>
    <mesh_term>Lurasidone Hydrochloride</mesh_term>
    <mesh_term>Asenapine</mesh_term>
    <mesh_term>Iloperidone</mesh_term>
    <mesh_term>Perphenazine</mesh_term>
    <mesh_term>Fluoxetine</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Healthy Lifestyle Information</title>
          <description>Participants will continue on current antipsychotic medication.&#xD;
Olanzapine, quetiapine, risperidone, ziprasidone, aripiprazole, asenapine, iloperidone, lurasidone, paliperidone, or olanzapine/fluoxetine: Current antipsychotic medication will be continued throughout the treatment period, with changes in dose only made as clinically indicated</description>
        </group>
        <group group_id="P2">
          <title>Switch Treatment + Healthy Lifestyle Instruction</title>
          <description>Participants will undergo a staggered switch from current antipsychotic medication to aripiprazole or perphenazine.&#xD;
Aripiprazole or Perphenazine: Baseline second generation antipsychotic (SGA) treatment will be gradually decreased and discontinued over 8 weeks while treatment with aripiprazole or perphenazine will be increased to effective levels.</description>
        </group>
        <group group_id="P3">
          <title>Metformin Treatment + Healthy Lifestyle Instruction</title>
          <description>Participants will add metformin to current antipsychotic medication treatment.&#xD;
Metformin: Metformin treatment will be added to current SGA treatment, with dosing based on participant weight and increased according to a preset titration schedule unless side effects interfere.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="47"/>
                <participants group_id="P2" count="31"/>
                <participants group_id="P3" count="49"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="34"/>
                <participants group_id="P2" count="19"/>
                <participants group_id="P3" count="37"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="13"/>
                <participants group_id="P2" count="12"/>
                <participants group_id="P3" count="12"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>127 subjects were randomized between 10/2009-10/2013 into three groups (CONTROL=47; MET=49; SWITCH=31). Safety analyses excluded 4 participants (CONTROL=1, MET=2, SWITCH=1) who discontinued at baseline. Primary efficacy analyses included 121 participants (CONTROL=44; MET=47; SWITCH=30) with ≥1 post-baseline vital sign measurement.</population>
      <group_list>
        <group group_id="B1">
          <title>Healthy Lifestyle Information</title>
          <description>Participants will continue on current antipsychotic medication.&#xD;
Olanzapine, quetiapine, risperidone, ziprasidone, aripiprazole, asenapine, iloperidone, lurasidone, paliperidone, or olanzapine/fluoxetine: Current antipsychotic medication will be continued throughout the treatment period, with changes in dose only made as clinically indicated</description>
        </group>
        <group group_id="B2">
          <title>Switch Treatment + Healthy Lifestyle Instruction</title>
          <description>Participants will undergo a staggered switch from current antipsychotic medication to aripiprazole or perphenazine.&#xD;
Aripiprazole or Perphenazine: Baseline second generation antipsychotic (SGA) treatment will be gradually decreased and discontinued over 8 weeks while treatment with aripiprazole or perphenazine will be increased to effective levels.</description>
        </group>
        <group group_id="B3">
          <title>Metformin Treatment + Healthy Lifestyle Instruction</title>
          <description>Participants will add metformin to current antipsychotic medication treatment.&#xD;
Metformin: Metformin treatment will be added to current SGA treatment, with dosing based on participant weight and increased according to a preset titration schedule unless side effects interfere.</description>
        </group>
        <group group_id="B4">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="47"/>
            <count group_id="B2" value="31"/>
            <count group_id="B3" value="49"/>
            <count group_id="B4" value="127"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="41"/>
                    <measurement group_id="B2" value="26"/>
                    <measurement group_id="B3" value="45"/>
                    <measurement group_id="B4" value="112"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                    <measurement group_id="B2" value="5"/>
                    <measurement group_id="B3" value="4"/>
                    <measurement group_id="B4" value="15"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="17"/>
                    <measurement group_id="B2" value="10"/>
                    <measurement group_id="B3" value="18"/>
                    <measurement group_id="B4" value="45"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="30"/>
                    <measurement group_id="B2" value="21"/>
                    <measurement group_id="B3" value="31"/>
                    <measurement group_id="B4" value="82"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                    <measurement group_id="B2" value="4"/>
                    <measurement group_id="B3" value="7"/>
                    <measurement group_id="B4" value="16"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="42"/>
                    <measurement group_id="B2" value="27"/>
                    <measurement group_id="B3" value="42"/>
                    <measurement group_id="B4" value="111"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="13"/>
                    <measurement group_id="B2" value="9"/>
                    <measurement group_id="B3" value="14"/>
                    <measurement group_id="B4" value="36"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="25"/>
                    <measurement group_id="B2" value="16"/>
                    <measurement group_id="B3" value="26"/>
                    <measurement group_id="B4" value="67"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="9"/>
                    <measurement group_id="B2" value="6"/>
                    <measurement group_id="B3" value="9"/>
                    <measurement group_id="B4" value="24"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Body Mass Index (BMI) Z-score Change</title>
        <time_frame>Change from baseline to 24 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Healthy Lifestyle Information</title>
            <description>Participants will continue on current antipsychotic medication.&#xD;
Olanzapine, quetiapine, risperidone, ziprasidone, aripiprazole, asenapine, iloperidone, lurasidone, paliperidone, or olanzapine/fluoxetine: Current antipsychotic medication will be continued throughout the treatment period, with changes in dose only made as clinically indicated</description>
          </group>
          <group group_id="O2">
            <title>Switch Treatment + Healthy Lifestyle Instruction</title>
            <description>Participants will undergo a staggered switch from current antipsychotic medication to aripiprazole or perphenazine.&#xD;
Aripiprazole or Perphenazine: Baseline second generation antipsychotic (SGA) treatment will be gradually decreased and discontinued over 8 weeks while treatment with aripiprazole or perphenazine will be increased to effective levels.</description>
          </group>
          <group group_id="O3">
            <title>Metformin Treatment + Healthy Lifestyle Instruction</title>
            <description>Participants will add metformin to current antipsychotic medication treatment.&#xD;
Metformin: Metformin treatment will be added to current SGA treatment, with dosing based on participant weight and increased according to a preset titration schedule unless side effects interfere.</description>
          </group>
        </group_list>
        <measure>
          <title>Body Mass Index (BMI) Z-score Change</title>
          <units>Z Score</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="44"/>
                <count group_id="O2" value="30"/>
                <count group_id="O3" value="47"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.040" spread="0.029"/>
                    <measurement group_id="O2" value="-0.112" spread="0.037"/>
                    <measurement group_id="O3" value="-0.088" spread="0.028"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Whole Body Insulin Sensitivity Index</title>
        <time_frame>Change from baseline to 24 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Healthy Lifestyle Information</title>
            <description>Participants will continue on current antipsychotic medication.&#xD;
Olanzapine, quetiapine, risperidone, ziprasidone, aripiprazole, asenapine, iloperidone, lurasidone, paliperidone, or olanzapine/fluoxetine: Current antipsychotic medication will be continued throughout the treatment period, with changes in dose only made as clinically indicated</description>
          </group>
          <group group_id="O2">
            <title>Switch Treatment + Healthy Lifestyle Instruction</title>
            <description>Participants will undergo a staggered switch from current antipsychotic medication to aripiprazole or perphenazine.&#xD;
Aripiprazole or Perphenazine: Baseline second generation antipsychotic (SGA) treatment will be gradually decreased and discontinued over 8 weeks while treatment with aripiprazole or perphenazine will be increased to effective levels.</description>
          </group>
          <group group_id="O3">
            <title>Metformin Treatment + Healthy Lifestyle Instruction</title>
            <description>Participants will add metformin to current antipsychotic medication treatment.&#xD;
Metformin: Metformin treatment will be added to current SGA treatment, with dosing based on participant weight and increased according to a preset titration schedule unless side effects interfere.</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Whole Body Insulin Sensitivity Index</title>
          <units>mU/L</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="44"/>
                <count group_id="O2" value="30"/>
                <count group_id="O3" value="47"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.74" spread="0.82"/>
                    <measurement group_id="O2" value="0.42" spread="0.91"/>
                    <measurement group_id="O3" value="-0.34" spread="0.65"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Triglyceride Levels</title>
        <time_frame>Change from baseline to 24 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Healthy Lifestyle Information</title>
            <description>Participants will continue on current antipsychotic medication.&#xD;
Olanzapine, quetiapine, risperidone, ziprasidone, aripiprazole, asenapine, iloperidone, lurasidone, paliperidone, or olanzapine/fluoxetine: Current antipsychotic medication will be continued throughout the treatment period, with changes in dose only made as clinically indicated</description>
          </group>
          <group group_id="O2">
            <title>Switch Treatment + Healthy Lifestyle Instruction</title>
            <description>Participants will undergo a staggered switch from current antipsychotic medication to aripiprazole or perphenazine.&#xD;
Aripiprazole or Perphenazine: Baseline second generation antipsychotic (SGA) treatment will be gradually decreased and discontinued over 8 weeks while treatment with aripiprazole or perphenazine will be increased to effective levels.</description>
          </group>
          <group group_id="O3">
            <title>Metformin Treatment + Healthy Lifestyle Instruction</title>
            <description>Participants will add metformin to current antipsychotic medication treatment.&#xD;
Metformin: Metformin treatment will be added to current SGA treatment, with dosing based on participant weight and increased according to a preset titration schedule unless side effects interfere.</description>
          </group>
        </group_list>
        <measure>
          <title>Triglyceride Levels</title>
          <units>mg/dL</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="44"/>
                <count group_id="O2" value="30"/>
                <count group_id="O3" value="47"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.2" spread="9.1"/>
                    <measurement group_id="O2" value="16.6" spread="12.0"/>
                    <measurement group_id="O3" value="14.7" spread="8.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Low Density Lipoprotein (LDL) Cholesterol Level</title>
        <time_frame>From Baseline to Week 24</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Healthy Lifestyle Information</title>
            <description>Participants will continue on current antipsychotic medication.&#xD;
Olanzapine, quetiapine, risperidone, ziprasidone, aripiprazole, asenapine, iloperidone, lurasidone, paliperidone, or olanzapine/fluoxetine: Current antipsychotic medication will be continued throughout the treatment period, with changes in dose only made as clinically indicated</description>
          </group>
          <group group_id="O2">
            <title>Switch Treatment + Healthy Lifestyle Instruction</title>
            <description>Participants will undergo a staggered switch from current antipsychotic medication to aripiprazole or perphenazine.&#xD;
Aripiprazole or Perphenazine: Baseline second generation antipsychotic (SGA) treatment will be gradually decreased and discontinued over 8 weeks while treatment with aripiprazole or perphenazine will be increased to effective levels.</description>
          </group>
          <group group_id="O3">
            <title>Metformin Treatment + Healthy Lifestyle Instruction</title>
            <description>Participants will add metformin to current antipsychotic medication treatment.&#xD;
Metformin: Metformin treatment will be added to current SGA treatment, with dosing based on participant weight and increased according to a preset titration schedule unless side effects interfere.</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Low Density Lipoprotein (LDL) Cholesterol Level</title>
          <units>mg/dL</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="44"/>
                <count group_id="O2" value="30"/>
                <count group_id="O3" value="47"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.6" spread="4.2"/>
                    <measurement group_id="O2" value="-8.1" spread="5.4"/>
                    <measurement group_id="O3" value="-4.1" spread="3.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <desc>See the correct numbers for the 3 populations below. We had to exclude 5 participants (CONTROL = 2, METFORMIN = 2, SWITCH = 1).&#xD;
Randomized population:&#xD;
Control - 47 Metformin - 49 Switch - 31&#xD;
Aripiprazole - 13 Molindone - 1 Perphenazine - 17&#xD;
Safety population:&#xD;
Control - 45 Metformin - 47 Switch - 30&#xD;
Aripiprazole - 12 Molindone - 1 Perphenazine - 17&#xD;
Efficacy population :&#xD;
Control - 44 Metformin - 47 Switch - 30&#xD;
Aripiprazole - 12 Molindone - 1 Perphenazine - 17</desc>
      <group_list>
        <group group_id="E1">
          <title>Healthy Lifestyle Information</title>
          <description>Participants will continue on current antipsychotic medication.&#xD;
Olanzapine, quetiapine, risperidone, ziprasidone, aripiprazole, asenapine, iloperidone, lurasidone, paliperidone, or olanzapine/fluoxetine: Current antipsychotic medication will be continued throughout the treatment period, with changes in dose only made as clinically indicated</description>
        </group>
        <group group_id="E2">
          <title>Switch Treatment + Healthy Lifestyle Instruction</title>
          <description>Participants will undergo a staggered switch from current antipsychotic medication to aripiprazole or perphenazine.&#xD;
Aripiprazole or Perphenazine: Baseline second generation antipsychotic (SGA) treatment will be gradually decreased and discontinued over 8 weeks while treatment with aripiprazole or perphenazine will be increased to effective levels.</description>
        </group>
        <group group_id="E3">
          <title>Metformin Treatment + Healthy Lifestyle Instruction</title>
          <description>Participants will add metformin to current antipsychotic medication treatment.&#xD;
Metformin: Metformin treatment will be added to current SGA treatment, with dosing based on participant weight and increased according to a preset titration schedule unless side effects interfere.</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="45"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="30"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="47"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Appendicitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="47"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Aggression</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="30"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="47"/>
              </event>
              <event>
                <sub_title>Hallucinations</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="30"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="47"/>
              </event>
              <event>
                <sub_title>Suicidal ideation</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="30"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="47"/>
              </event>
              <event>
                <sub_title>Hospitalization</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="30"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="47"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Asthma attack</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="47"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Surgical and medical procedures</title>
            <event_list>
              <event>
                <sub_title>Femur Fracture</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="45"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="47"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="45" subjects_at_risk="45"/>
                <counts group_id="E2" subjects_affected="30" subjects_at_risk="30"/>
                <counts group_id="E3" subjects_affected="47" subjects_at_risk="47"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal pain or discomfort</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E3" events="5" subjects_affected="5" subjects_at_risk="47"/>
              </event>
              <event>
                <sub_title>Vomiting or nausea</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E3" events="4" subjects_affected="4" subjects_at_risk="47"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Infection</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="45"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="30"/>
                <counts group_id="E3" events="8" subjects_affected="8" subjects_at_risk="47"/>
              </event>
              <event>
                <sub_title>Acne</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="45"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="30"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="47"/>
              </event>
              <event>
                <sub_title>Energy increased</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="30"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="47"/>
              </event>
              <event>
                <sub_title>Injury</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="45"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="30"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="47"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Agitation</sub_title>
                <counts group_id="E1" events="8" subjects_affected="8" subjects_at_risk="45"/>
                <counts group_id="E2" events="6" subjects_affected="6" subjects_at_risk="30"/>
                <counts group_id="E3" events="5" subjects_affected="5" subjects_at_risk="47"/>
              </event>
              <event>
                <sub_title>Hypersomnia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="45"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="30"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="47"/>
              </event>
              <event>
                <sub_title>Restlessness</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="45"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="47"/>
              </event>
              <event>
                <sub_title>Sedation</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="45"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="30"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="47"/>
              </event>
              <event>
                <sub_title>Initial Insomnia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="45"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="30"/>
                <counts group_id="E3" events="3" subjects_affected="3" subjects_at_risk="47"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Aggression or hostility</sub_title>
                <counts group_id="E1" events="10" subjects_affected="10" subjects_at_risk="45"/>
                <counts group_id="E2" events="6" subjects_affected="6" subjects_at_risk="30"/>
                <counts group_id="E3" events="3" subjects_affected="3" subjects_at_risk="47"/>
              </event>
              <event>
                <sub_title>Anger or irritability</sub_title>
                <counts group_id="E1" events="9" subjects_affected="9" subjects_at_risk="45"/>
                <counts group_id="E2" events="6" subjects_affected="6" subjects_at_risk="30"/>
                <counts group_id="E3" events="5" subjects_affected="5" subjects_at_risk="47"/>
              </event>
              <event>
                <sub_title>Impulse-control disorder</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="45"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="30"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="47"/>
              </event>
              <event>
                <sub_title>Negativism</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="45"/>
                <counts group_id="E2" events="5" subjects_affected="5" subjects_at_risk="30"/>
                <counts group_id="E3" events="6" subjects_affected="6" subjects_at_risk="47"/>
              </event>
              <event>
                <sub_title>Frustration</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="45"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="30"/>
                <counts group_id="E3" events="4" subjects_affected="4" subjects_at_risk="47"/>
              </event>
              <event>
                <sub_title>Anxiety</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="45"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="30"/>
                <counts group_id="E3" events="6" subjects_affected="6" subjects_at_risk="47"/>
              </event>
              <event>
                <sub_title>Mood swings</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="45"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="30"/>
                <counts group_id="E3" events="4" subjects_affected="4" subjects_at_risk="47"/>
              </event>
              <event>
                <sub_title>Obsessive rumination</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="30"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="47"/>
              </event>
              <event>
                <sub_title>Depressed Mood</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="45"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="30"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="47"/>
              </event>
              <event>
                <sub_title>Hallucination</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="45"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="30"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="47"/>
              </event>
              <event>
                <sub_title>Disturbance in attention</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="45"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E3" events="4" subjects_affected="4" subjects_at_risk="47"/>
              </event>
              <event>
                <sub_title>Suicidal ideation</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="45"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="30"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="47"/>
              </event>
              <event>
                <sub_title>Psychomotor hyperactivity</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="45"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="30"/>
                <counts group_id="E3" events="3" subjects_affected="3" subjects_at_risk="47"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Rash</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="45"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="30"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="47"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>27 subjects were randomized between 10/2009-10/2013 into three groups (CONTROL=47; MET=49; SWITCH=31). Safety analyses excluded 4 participants (CONTROL=1, MET=2, SWITCH=1) who discontinued at baseline.</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Dr. Mark Riddle</name_or_title>
      <organization>Johns Hopkins University</organization>
      <phone>410-302-6120</phone>
      <email>mriddle1@jhmi.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

